...recurrence. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Lamisil to treat onychomycosis and tinea capitis. MedPharm Ltd....

...Moberg received an exclusive, worldwide license to use MedPharm's MedSpray sprayable drug delivery technology to develop...
...development, for which it will receive consulting and development fees. Further terms were not disclosed. MedPharm Ltd....

...next year, MedPharm will begin a Phase II trial of MedSpray using an undisclosed antifungal. MedPharm Ltd....

...OptiNose's nasal delivery technology with MedPharm's capabilities in formulating poorly soluble drugs and powder engineering. MedPharm Ltd....

...KSB will develop with MedPharm a solid suppository formulation of its KSB304 antibody to treat ulcerative...
...be associated with inflammatory responses in ulcerative colitis. KS Biomedix Holdings plc (LSE:KSB), London, U.K MedPharm Ltd....

...KS Biomedix (LSE:KSB) will develop with MedPharm (London, U.K.) a solid suppository dosage form of its...